Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.68 |
| ▸ | TUBB | P07437 | 1/20 | 0.68 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.68 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.68 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.68 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.68 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.68 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.68 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.68 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.68 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.68 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.68 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.68 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.68 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5346065 | 1.00 | TUBB4A (0.68) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5573795 | 0.91 | TUBB4A (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL2245487 | 0.86 | TUBB4A (0.65) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5570405 | 0.82 | TUBB4A (0.68) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Indibulin SCHEMBL29355017 | 0.81 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Indibulin SCHEMBL3165856 | 0.81 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5573030 | 0.81 | TUBB4A (0.65) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5572473 | 0.81 | TUBB4A (0.65) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5569338 | 0.80 | TUBB4A (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5569320 | 0.80 | TUBB4A (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656588-A2 | ENHANCED NANOPARTICLE DELIVERY SYSTEMS | Children's Hospital Medical Center (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250340879-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID TRANSFER | CHILDRENS HOSPITAL MED CT (US) | 2025-11-06 | — | — | US | claimed |
| US-12378550-B2 | Compositions and methods for nucleic acid transfer | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2025-08-05 | — | — | US | claimed |
| EP-4702027-A1 | 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINE C-NUCLEOSIDE COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260000618-A1 | PHARMACEUTICAL FORMULATIONS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4656588-A2 | ENHANCED NANOPARTICLE DELIVERY SYSTEMS | Children's Hospital Medical Center (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250340879-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID TRANSFER | CHILDRENS HOSPITAL MED CT (US) | 2025-11-06 | — | — | US | disclosed |
| US-12448383-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250296936-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-09-25 | — | — | US | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230270665-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC | 2023-08-31 | — | — | US | disclosed |
| EP-4171518-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11433022-B2 | Rapidly-orodispersible tablets having an in interior cavity | Aprecia Pharmaceuticals LLC (US) | 2022-09-06 | — | — | US | disclosed |
| WO-2022125784-A1 | ENHANCED NANOPARTICLE DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-06-16 | — | — | WO | disclosed |
| EP-3981392-A1 | CONTROLLED RELEASE DOSAGE FORM | Triastek, Inc. (CN) | 2022-04-13 | — | — | EP | disclosed |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | Triastek, Inc. (CN) | 2022-03-22 | — | — | US | disclosed |
| US-20220054409-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TUBB4A 717/4885TUBB 490/4885TUBA3C 449/4885 |
| US-20260000618-A1 | PHARMACEUTICAL FORMULATIONS AND USES THEREOF | PRNP, F7, F5 | TUBB4A 3729/4885TUBB 4121/4885TUBA3C 4134/4885 |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | CYP2D6, CYP3A7, CYP3A5 | TUBB4A 4198/4885TUBB 3862/4885TUBA3C 4438/4885 |
| US-12448383-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | TUBB4A 717/4885TUBB 490/4885TUBA3C 449/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | TUBB4A 4847/4885TUBB 4797/4885TUBA3C 4165/4885 |
| US-20250340879-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID TRANSFER | SNRPE, RNASE1, POLRMT | TUBB4A 654/4885TUBB 349/4885TUBA3C 549/4885 |
| US-20250296936-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | TUBB4A 4813/4885TUBB 4724/4885TUBA3C 3944/4885 |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | TUBB4A 717/4885TUBB 490/4885TUBA3C 449/4885 |
| US-12378550-B2 | Compositions and methods for nucleic acid transfer | SNRPE, RNASE1, POLRMT | TUBB4A 654/4885TUBB 349/4885TUBA3C 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.